Bioengineers and public health researchers at Harvard University have developed a novel spraying method for delivering the most common tuberculosis (TB) vaccine, providing a new low-cost and scaleable technique that offers needle-free delivery and greater stability at room temperature than existing methods.
The process could one day provide a better approach for vaccination against TB and help prevent the related spread of HIV/AIDS in the developing world.
Researcher David Edwards will describe the finding -- and ongoing work to encourage widespread use of the new vaccine in the developing world -- this week at the annual meeting of the American Association for the Advancement of Science in San Francisco.
Edwards, an international leader in aerosol drug and vaccine delivery, sees great promise for the advance, which he and his colleagues hope to develop in the next few years through a partnership with the international not-for-profit Medicine in Need (MEND), based in Cambridge, Mass., Paris, and Cape Town.
His research, as well as the efforts to distribute the new vaccine in conjunction with MEND, are supported by a Grand Challenge Grant from the Bill and Melinda Gates Foundation.
"With the increasing incidence of tuberculosis and drug-resistant disease in developing countries due to HIV/AIDS, there is a need for vaccines that are more effective than the present Bacillus Calmette-Guerin (BCG) vaccine," says Edwards, the Gordon McKay Professor of the Practice of Biomedical Engineering in Harvard's School of Engineering and Applied Sciences. "An optimal new vaccine would provide a safe and more consistent degree of protection by eliminating needle injection and refrigerated storage."